MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, today announced ...

Anavex Life Sciences faces regulatory setbacks after the EMA adopted a negative opinion of blarcamesine in Alzheimer's. Find ...

These solutions offer full-chain technology transfer, covering everything from core raw materials and reagent solutions to ...

Comprehensive residue-level mapping of amyloid-beta recognition reveals how sequence variants, post-translational modifications, and aggregation state shape antibody specificity, thereby guiding ...

In this video, James E. Galvin, MD, MPH, professor of neurology and psychiatry and behavioral sciences at the University of Miami Miller School of Medicine, discusses how the treatment landscape for ...

Thank you, Clint, and good morning, everyone. As we enter 2026, we continue to progress our innovative clinical pipeline with a particular focus on our lead candidate, oral blarcamesine, in early ...

MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, today announced positive Phase 1 results for TML-6 ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2026 Earnings Call Transcript February 9, 2026 Anavex Life Sciences Corp. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.1.

Campaigners have blasted the move as a "major disappointment”.

Anavex Life Sciences (NASDAQ:AVXL) executives used the company’s fiscal 2026 first-quarter earnings call to outline regulatory next steps for oral blarcamesine in early Alzheimer’s disease and to revi ...

Q1 2026 earnings call: blarcamesine Alzheimer’s FDA/EMA timeline, ACCESS-AD partnership, and $131.7M cash runway—read now.

Dr Ray O’Connor continues his look at the latest clinical articles on disease prevention, with a particular emphasis on diet and health ...